目次

Table of Content

1. Brief Introduction To CDC7 Kinase Inhibitors
1.1 Overview
1.2 History and Emergence of CDC7 Kinase Inhibitors

2. Global CDC7 Kinase Inhibitors Market and Clinical Trends by Indications
2.1 Leukemia
2.2 Colorectal Cancer
2.3 Pancreatic Cancer

3. Global CDC7 Inhibitors Market Outlook
3.1 Current Market Outlook
3.2 Future Market Opportunity

4. CDC7 Kinase Inhibitors Market Trend By Region
4.1 China
4.2 Japan
4.3 UK
4.4 US

5. Global CDC7 Protein Kinase Inhibitors Clinical Trials Overview
5.1 By Country
5.2 Indication
5.3 Phase
5.4 Therapy Class

6. Global CDC7 Protein Kinase Inhibitors Clinical Pipeline By Company, Indication and Phase
6.1 Phase-I
6.2 Phase-I/II

7. Global CDC7 Kinase Inhibitor Market Dynamics
7.1 Market Drivers
7.2 Market Challenges

8. Competitive Landscape
8.1 Carna Biosciences
8.2 Chia Tai Tianqing Pharmaceutical Group
8.3 Eli Lilly
8.4 Memorial Sloan-Kettering Cancer Center
8.5 Schrodinger

List of Figures & Tables
Figure 1-1: CDC7 Kinase Inhibitor - Mechanism of Action
Figure 1-2: Comparison of CDC7 Inhibitors With Conventional Methods
Figure 1-3: CDC7 Inhibitor Development
Figure 2-1: LBS-007 Phase I/II Study - Initiation and Completion Year
Figure 2-2: Schrandouml;dinger Drug Discovery Approach
Figure 2-3: SGR-2921 Phase I Study - Initiation and Completion Year
Figure 2-4: TAK-931 Phase II Trials Commencement
Figure 2-5: Ongoing CDC7 Inhibitors Candidates - Mode Of Action
Figure 2-6: LY3143921 hydrate Phase I Study - Initiation and Completion Year
Figure 2-7: TQB3824 Phase I Study - Initiation and Completion Year
Figure 2-8: CDC7 Inhibitor For The Treatment Of Pancreatic Cancer
Figure 3-1: Global CDC7 Inhibitor - Current Ongoing Candidates In Trials
Figure 3-2: Global CDC7 Inhibitors Market - Future Aspects
Figure 4-1: Candidates Developed By Nerviano Medical Science
Figure 4-2: Aspects For The Inclining Growth Of CDC7 Inhibitors In China
Figure 4-3: AS-0141: Mechanism Of Action
Figure 4-4: Timeline Of AS-0141
Figure 4-5: Ongoing Research Conducted By Cancer Research Horizon
Figure 4-6: US - Cancer Incidences and Deaths, 2023
Figure 5-1: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Country
(Numbers), 2023 and 2024
Figure 5-2: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Indication
(Numbers), 2023 and 2024
Figure 5-3: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Phase
(Numbers), 2023 and 2024
Figure 5-4: Global - CDC7 Protein Kinase Inhibitors Clinical Trials by Therapy Class
(Numbers), 2023 and 2024
Figure 7-1: Global - CDC7 Inhibitor Market Drivers
Figure 7-2: Global - CDC7 Inhibitor Market Challenges

List of Tables
Table 2-1: Leukemia Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
Table 2-2: Colorectal Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
Table 2-3: Pancreatic Cancer - CDC7 Kinase Inhibitor Ongoing Clinical Trials
Table 4-1: China - CDC7 Kinase Inhibitor Ongoing Preclinical and Clinical Trials
Table 4-2: Japan - CDC7 Kinase Inhibitor Ongoing Clinical Trials
Table 4-3: UK - CDC7 Kinase Inhibitor Ongoing Clinical Trials